The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 801–900 of 1,008
Blacklock, C. L., Hirst, J. A., Taylor, K., Stevens, R., Roberts, N. W., & Farmer, A. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03341.x · Cited by 36
Diagnosis and Treatment of Diabetic Kidney Disease
Gosmanov, A. R., Wall, B. M., & Gosmanova, E. O. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000185 · Cited by 44
Frequency of albuminuria in primary care: a cross-sectional study
Bramlage, P., Pittrow, D. B., Lehnert, H., Höfler, M., Kirch, W., Ritz, E., & Wïttchen, H. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000224489.03221.de · Cited by 38
Self-citationACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
Perico, N., Ruggenenti, P. L., & Remuzzi, G. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.03.006 · Cited by 44
Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension
Opie, L. H. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06879-9 · Cited by 36
Renal Consequences of Diabetes After Kidney Donation
Ibrahim, H. N., Berglund, D. M., Jackson, S., Vock, D. M., Foley, R. N., & Matas, A. J. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14416 · Cited by 35
“Moreover, the rate of GFR change in diabetic donors is similar to two-kidney hypertensive microalbuminuric diabetics such as the participants of the Irbesartan Diabetic Nephropathy Trial (27).”
ResultMicroRNA-215: From biology to theranostic applications
Vychytilova‐Faltejskova, P., & Slabý, O. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.03.002 · Cited by 37
Nonproteinuric Diabetic Nephropathy
Dwyer, J. P., & Lewis, J. B. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.006 · Cited by 35
Volpe, M., Tocci, G., Sciarretta, S., Verdecchia, P., Trimarco, B., & Mancia, G. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832961ed · Cited by 35
Silent Ischemia in People With Diabetes: A Condition That Must Be Heard
Tabibiazar, R., & Edelman, S. V. (2003) · Clinical Diabetes · doi:10.2337/diaclin.21.1.5 · Cited by 45
Proteinuria in diabetic nephropathy: Treatment and evolution
Campbell, R. C., Ruggenenti, P. L., & Remuzzi, G. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0014-0 · Cited by 39
Role of Angiotensin II in the Evolution of Diastolic Heart Failure
Chinnaiyan, K. M., Alexander, D., & McCullough, P. A. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04889.x · Cited by 39
Viazzi, F. C., Muiesan, M. L., Schillaci, G., Salvetti, M., Pucci, G., Bonino, B., Signori, A., & Pontremoli, R. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000991 · Cited by 38
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
Lonn, E. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0074-7 · Cited by 56
Strategies to Retard the Progression of Chronic Kidney Disease
Zandi‐Nejad, K., & Brenner, B. M. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.001 · Cited by 36
Derosa, G., Cicero, A. F. G., Ciccarelli, L., & Fogari, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80201-1 · Cited by 38
Sleight, P., & Yusuf, S. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00001 · Cited by 39
Validation of the CDC-RTI Diabetes Cost-Effectiveness Model
Hoerger, T. J., Segel, J. E., Zhang, P., & Sorensen, S. W. (2009) · doi:10.3768/rtipress.2009.mr.0013.0909 · Cited by 39
Gaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 46
Ruzicka, M., Quinn, R. R., McFarlane, P., Hemmelgarn, B. R., Prasad, G. V. R., Feber, J., NESRALLAH, G. E., MacKinnon, M., Tangri, N., McCormick, B. B., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.03.003 · Cited by 36
“(Heart Outcomes Prevention Evaluation) trial,(34) the CASE-J (Candesartan Antihypertensive Survival Evaluation in Japan) trial,(35) TRANSCEND (Telmisartan Randomised Assessment Study in Subjects with Cardiovascular Disease),(36) as well as the Makino et al(37) study, and the IDNT (Irbesartan in Development of Nephropa…”
BackgroundDecrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats
Okumura, M., Masada, M., Yoshida, Y., Shintaku, H., Hosoi, M., Okada, N., Konishi, Y., Morikawa, T., Miura, K., & Imanishi, M. (2006) · Kidney International · doi:10.1038/sj.ki.5000431 · Cited by 34
Gaggl, M., Cejka, D., Plischke, M., Heinze, G., Fraunschiel, M., Schmidt, A., Hörl, W. H., & Sunder–Plassmann, G. (2013) · Trials · doi:10.1186/1745-6215-14-196 · Cited by 36
“angiotensin-II-receptor antagonists slows the progression of decline in renal function [1-5].”
BackgroundDihydropyridine calcium channel blockers and renal disease
Robles, N. R., Fıcı, F., & Grassi, G. M. (2016) · Hypertension Research · doi:10.1038/hr.2016.85 · Cited by 38
Emerging therapeutics for the treatment of diabetic nephropathy
Brenneman, J. B., Hill, J., & Pullen, S. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.079 · Cited by 36
Al-Kuraishy, H. M., Al-Gareeb, A. I., & Al-Naimi, M. S. (2019) · Journal of Laboratory Physicians · doi:10.4103/jlp.jlp_136_18 · Cited by 34
“Entertainingly, clinical trials involving Irbesartan in hypertensive patients and in Diabetic Nephropathy Trial study illustrated that irbesartan revealed effective renoprotective effect through regulation of peroxisome proliferator‐activator receptor‐gamma (PPAR‐γ).[24] Similarly, irbesartan shows a renoprotective ef…”
BackgroundLong-term outcomes of kidney donors
Morgan, B. R., & Ibrahim, H. N. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32834bd72b · Cited by 34
“nondiabetic donors (with a similar duration after the uninephrectomy) and the published rates in microalbuminuric diabetics with two kidneys [28].”
ResultRosen, A. B. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00351.x · Cited by 36
Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers
Sierra, C., & de la Sierra, A. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000174397.59100.89 · Cited by 36
Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus
Araki, S., Haneda, M., Koya, D., Kashiwagi, A., Uzu, T., & Kikkawa, R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.031 · Cited by 38
Cederholm, J., Zethelius, B., Nilsson, P. M., Eeg‐Olofsson, K., Eliasson, B., & Guðbjörnsdóttir, S. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.07.003 · Cited by 39
Mallat, S. G. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-32 · Cited by 39
“For example, the IRbesartan in patients with type II diabetes and MicroAlbuminuria (IRMA2) study demonstrated that irbesartan, added to other antihypertensive agents, could prevent the development of diabetic nephropathy in hypertensive patients with T2DM and persistent microalbuminuria [118].”
BackgroundDatzmann, T., Fuchs, S., Andrée, D., Hohenstein, B., Schmitt, J. M., & Schindler, C. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.04.019 · Cited by 37
Siebenhofer, A., Plank, J., Horvath, K., Berghold, A., Sutton, A. J., Sommer, R., & Pieber, T. R. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01122.x · Cited by 34
Pan, C., Ho, L. T., Soegondo, S., Prodjosudjadi, W., Suwanwalaikorn, S., Lim, S. C., Chan, T. M., Chow, K. W. S., Thoenes, M., Choi, D. S., et al. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0296 · Cited by 37
Ferrari, P. (2007) · Nephrology · doi:10.1111/j.1440-1797.2006.00749.x · Cited by 34
Franco, V., Oparil, S., & Carretero, O. A. (2004) · Circulation · doi:10.1161/01.cir.0000132615.44103.b1 · Cited by 39
Brenner, B. M., & Zagrobelny, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s83.16.x · Cited by 34
Estimation of the Glomerular Filtration Rate in Cancer Patients: A New Formula for New Drugs
Murray, P. T., & Ratain, M. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.083 · Cited by 34
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 45
Feldman, D. L. (2010) · Hypertension Research · doi:10.1038/hr.2010.19 · Cited by 37
Uzu, T., Sakaguchi, M., Yokomaku, Y., Kume, S., Kanasaki, M., Isshiki, K., Araki, S., Sugiomoto, T., Koya, D., Haneda, M., et al. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0157-7 · Cited by 36
Rossi, G. P., Seccia, T. M., Barton, M., Danser, A. H. J., de Leeuw, P. W., Dhaun, N., Rizzoni, D., Rossignol, P., Ruilope, L. M., van den Meiracker, A. H., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001599 · Cited by 35
EGCG-derived polymeric oxidation products enhance insulin sensitivity in db/db mice
Wu, X., Yang, M., He, Y., Wang, F., Kong, Y.-S., Ling, T.-J., & Zhang, J. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102259 · Cited by 36
“Moreover, abnormal RAS in the kidney increases the progression of diabetic nephropathy towards end-stage renal disease in patients with T2D [63,64], while abnormal RAS in the pancreatic islets reduces islet blood flow and insulin biosynthesis, impairs β-cell secretory function and cell mass, and increases oxidative st…”
BackgroundCurovic, V. R., Jongs, N., Kroonen, M. Y. A. M., Zobel, E. H., Hansen, T. W., Sen, T., Laverman, G. D., Kooy, A., Persson, F., Rossing, P. R., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1699 · Cited by 65
Role of Smad1 in diabetic nephropathy: Molecular mechanisms and implications as a diagnostic marker.
Abe, H., Matsubara, T., Arai, H., & Doi, T. (2011) · PubMed · doi:10.14670/hh-26.531 · Cited by 34
Advanced glycation end products and vascular structure and function
Soldatos, G., & Cooper, M. E. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0025-8 · Cited by 35
The value of irbesartan in the management of hypertension
Bramlage, P., Durand‐Zaleski, I., Desai, N., Pirk, O., & Hacker, C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903103820 · Cited by 36
Heerspink, H. J. L., Fowler, M. J., Volgi, J., Reutens, A. T., Klein, I., Herskovits, T., Packham, D., Fraser, I. R., Schwartz, S. L., Abaterusso, C., et al. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02249.x · Cited by 33
Slowing the progression of renal failure
Praga, M. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.5.x · Cited by 36
Baroletti, S. A., Gabardi, S., Magee, C., & Milford, E. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.6.788.32180 · Cited by 33
HRT does not improve urinary albumin excretion in postmenopausal diabetic women
Manning, P. J., Sutherland, W. H. F., Allum, A. R., de Jong, S. A., & Jones, S. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00279-6 · Cited by 33
Diabetic Kidney Disease and the Cardiorenal Syndrome
Jindal, A., Garcia‐Touza, M., Jindal, N., Whaley‐Connell, A. T., & Sowers, J. R. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.002 · Cited by 37
“However, in the presence of reduced blood pressure in DKD, use of pharmacologic strategies with interruption of the RAS with ACE inhibitors or ARBs is a primary risk-reduction strategy.23,42–45 Available data suggest that ARBs might have renal benefits independent of the SBP decreasing effect in patients with T2DM.43,…”
InfluentialOlmesartan medoxomil: current status of its use in monotherapy
Brunner, H. R. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.4.327 · Cited by 34
Renin-Angiotensin-Aldosterone System Inhibition
Mercier, K., Smith, H. D., & Biederman, J. I. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.002 · Cited by 37
Slowing the progression of diabetic nephropathy and its cardiovascular consequences
McCullough, P. A., Bakris, G. L., Owen, W. F., Klassen, P., & Califf, R. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.042 · Cited by 32
Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease
Slagman, M. C. J., Navis, G. J., & Laverman, G. D. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283361887 · Cited by 32
A Nonpeptide Angiotensin II Type 2 Receptor Agonist Prevents Renal Inflammation in Early Diabetes
Matavelli, L. C., Zatz, R., & Siragy, H. M. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000207 · Cited by 34
Cardiovascular and Renal Links along the Cardiorenal Continuum
García‐Donaire, J. A., & Ruilope, L. M. (2011) · International Journal of Nephrology · doi:10.4061/2011/975782 · Cited by 34
“Furthermore, the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA-2) study showed that treatment with the ARB irbesartan was much more effective than conventional therapy at both preventing the development of clinical proteinuria and favoring regression to normoalbuminuria in patients with microa…”
BackgroundChu, L., Fuller, M. T., Jervis, K., Ciaccia, A., & Abitbol, A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.015 · Cited by 43
Targets to retard the progression of diabetic nephropathy
Cooper, M. E., Jandeleit-Dahm, K. A. M., & Thomas, M. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00555.x · Cited by 32
Esnault, V. L. M., Ekhlas, A., Nguyen, J., & Moranne, O. P. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp776 · Cited by 36
Malinin, A., ONG, S., Makarov, L. M., PETUKHOVA, E. Y., & Serebruany, V. L. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01063.x · Cited by 32
Diabetes and Heart Disease: An Evidence-Driven Guide to Risk Factors Management in Diabetes
Lteif, A. A., Mather, K. J., & Clark, C. M. (2003) · Cardiology in Review · doi:10.1097/01.crd.0000086892.07437.05 · Cited by 39
Shoda, J., Kanno, Y., & Suzuki, H. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1515 · Cited by 32
Schmittdiel, J. A., Vijan, S. S., Fireman, B. H., Lafata, J. E., Oestreicher, N., & Selby, J. V. (2007) · Medical Care · doi:10.1097/01.mlr.0000254582.85666.01 · Cited by 32
Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Diabetes
Brotman, D. J., Girod, J. P., & Thomas, S. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480318 · Cited by 32
Microalbuminuria as a risk factor: the influence of renin–angiotensin system blockade
Menne, J., Chatzikyrkou, C., & Haller, H. G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833c206d · Cited by 35
Sim, J. J., Shi, J. M., Calara, F., Rasgon, S. A., Jacobsen, S., & Kalantar‐Zadeh, K. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834bbc8a · Cited by 32
Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade
Volpe, M., Cosentino, F., Tocci, G., Palano, F., & Paneni, F. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0205-z · Cited by 32
MACGREGOR, M. S., & Taal, M. W. (2011) · Nephron Clinical Practice · doi:10.1159/000328062 · Cited by 34
Benefits of the RAS blockade: clinical evidence before the ONTARGET study
Perret‐Guillaume, C., Joly, L., Jankowski, P., & Bénétos, A. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000354511.14086.f1 · Cited by 31
Guo, X., Zhou, G., Guo, M., Cheung, A. K., Huang, Y., & Beddhu, S. (2014) · Physiological Reports · doi:10.1002/phy2.230 · Cited by 31
“Despite the use of angiotensin-converting enzymes inhibitors or angiotensin receptor blockers (Brenner et al. 2001; Parving et al. 2001), diabetic nephropathy progression is common.”
Batenburg, W. W., van den Heuvel, M., van Esch, J. H. M., van Veghel, R., Garrelds, I. M., Leijten, F. P. J., & Danser, A. H. J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835c1789 · Cited by 31
“T he renin–angiotensin (Ang) system (RAS) contributes to the pathogenesis of diabetic nephropathy, since RAS blockers prevent the deterioration of renal function in patients with diabetes mellitus [1,2].”
Hamon, S., Griffin, T. P., Islam, M. N., Wall, D., Griffin, M. D., & O’Shea, P. M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0534 · Cited by 32
“These markers may facilitate cardiovascular risk stratification and the introduction of therapy at an earlier time point to reduce renal risk [20-22].”
BackgroundNephrology: 4. Strategies for the care of adults with chronic kidney disease.
Stigant, C. E., Stevens, L., & Levin, A. (2003) · Europe PMC (PubMed Central) · Cited by 39
Maddirala, S., Khan, A., Vincent, A. S., & Lau, K. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181836ac7 · Cited by 36
Microalbuminuria and urinary albumin excretion: French clinical practice guidelines
Halimi, J.-M., Hadjadj, S., Aboyans, V., Allaert, F., Artigou, J. Y., Beaufils, M., Berrut, G., Fauvel, J. P., Gin, H., Nitenberg, A., et al. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.06.001 · Cited by 35
Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead
Kalaitzidis, R., & Bakris, G. L. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00184.x · Cited by 32
Yoneda, M., Sanada, H., Yatabe, J., Midorikawa, S., Hashimoto, S., Sasaki, M., Katoh, T., Watanabe, T., Andrews, P. M., José, P. A., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000171587.44736.ba · Cited by 31
Type 2 diabetes mellitus: prevention of macrovascular complications
Meeuwisse-Pasterkamp, S. H., van der Klauw, M. M., & Wolffenbuttel, B. H. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.323 · Cited by 38
Völler, H., Reibis, R. K., Pittrow, D., Jannowitz, C., Wegscheider, K., Karmann, B., & Bestehorn, K. P. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902801360 · Cited by 35
Nakamura, T., Kanno, Y., Takenaka, T., & Suzuki, H. (2005) · Hypertension Research · doi:10.1291/hypres.28.415 · Cited by 32
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300610 · Cited by 32
Slowing the Progression of Adult Chronic Kidney Disease: Therapeutic Advances
Taal, M. W. (2004) · Drugs · doi:10.2165/00003495-200464200-00002 · Cited by 33
Transforming growth factor-beta as a treatment target in renal diseases.
Fukuda, N., Tahira, Y., Matsuda, H., & Matsumoto, K. (2009) · PubMed · Cited by 31
Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-β1
Cohen, M. P., Ziyadeh, F. N., Hong, S. W., Shearman, C. W., Hud, E., Lautenslager, G. T., de la Cruz, M. D. C. I., & Chen, S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00352.x · Cited by 31
Angiotensin II receptor blockers for the treatment of hypertension
See, S. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.11.1795 · Cited by 31
Longhitano, E., Calabrese, V., Casuscelli, C., Carlo, S. D., Maltese, S., Romeo, A., Calanna, M., Conti, G., & Santoro, D. (2024) · Medicina · doi:10.3390/medicina60111821 · Cited by 46
Liu, Q., Cui, Z., Deng, C., Yang, C., & Tao, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1485190 · Cited by 36
Mansour, M. H., Al‐Qattan, K. K., Thomson, M., & Ali, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0139-3 · Cited by 33
Effects of Probiotics on Diabetic Nephropathy: A Systematic Review
Vlachou, E. D., Ntikoudi, A., Govina, O., Lavdaniti, M., Kotsalas, N., Tsartsalis, A. N., & Dimitriadis, G. (2020) · Current Clinical Pharmacology · doi:10.2174/1574884715666200303112753 · Cited by 36
When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
Chan, E. Y.-H., Ma, A. L.-T., & Tullus, K. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04788-w · Cited by 30
Harloff, M., Prüschenk, S., Seifert, R., & Schlossmann, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15425 · Cited by 32
Farsang, C. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23468 · Cited by 37
Is kidney injury a reversible process?
Chatziantoniou, C., & Dussaule, J. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f1bb69 · Cited by 30
Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark
Sørensen, V. R., Hansen, P. M., Heaf, J. G., & Feldt‐Rasmussen, B. (2006) · Kidney International · doi:10.1038/sj.ki.5001516 · Cited by 35
McCullough, P. A., & Verrill, T. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2119 · Cited by 38
Jerums, G., Allen, T. J., Campbell, D. J., Cooper, M. E., Gilbert, R. E., Hammond, J. J., O’Brien, R. C., Jf, R., Tsalamandris, C., & The Melbourne Diabetic Nephropathy Study Group (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01316.x · Cited by 32
Capítulo 14 – Crise Hipertensiva
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160164 · Cited by 33
Weir, M. R. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002254 · Cited by 31
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.